



Professor Claire Harrison graduated from Oxford University Medical School and became a consultant at the Guy's and St Thomas Hospital in 2001, where she is now a deputy medical director.

The focus of her clinical work is myeloproliferative neoplasms (MPN), for which she has a national and international reputation. Key areas of interest are clinical trials and associated translational research. In addition to the PT-1 trial, MAJIC, COMFORT-II, JAKARTA-2 and PERSIST-1 where she is currently the global chief or co-chief investigator, she has a leadership role in over 20 clinical trials. This work has led to the approval of new therapies such as ruxolitinib, fedratinib and pacritinib. Translational research has been supported with a grant income of over £10M in the past 5 years. JAK2 exon 12 mutations, genetic susceptibility and the impact of the order of mutations in MPN. In the past 10 years she has published widely (>250 academic articles).

In addition she has a strong interest in patient advocacy and founded the UK MPN group www.mpnvoice.org.uk.

The clinical MPN service at GSTT is large, comprehensive and is internationally recognised as a centre of excellence.